Shionogi & Co., Ltd.

2019/07/29: Financial Results for the First Quarter of FY2019
2019/07/22: Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa
2019/07/19: Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
2019/06/24: Shionogi Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lusutrombopag, a Thrombopoietin Receptor Agonist and Epertinib, an HER2/EGFR Inhibitor
2019/06/19: SHIONOGI AND FERRER CONCLUDE A CONTRACT FOR THE PROMOTION IN SPAIN OF RIZMOIC® (NALDEMEDINE), A THERAPEUTIC AGENT FOR OPIOID-INDUCED CONSTIPATION
2019/06/18: Announcement about the Adjustment of the Conversion Value for Euro-Yen Denominated Convertible Bonds Maturing in 2019
2019/06/18: Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
2019/06/18: Shionogi Got Approval of Additional Indication of INTUNIV® in Japan for Treatment of Adult ADHD
2019/06/18: Shionogi to Present Cefiderocol and COT-143 Data at American Society for Microbiology Microbe 2019 Meeting
2019/06/13: Shionogi Purchases All Outstanding Shares of Pionnier following the Conclusion of their Joint Study
2019/06/04: Shionogi Announces Positive Top-Line Results for XOFLUZA® (Baloxavir Marboxil) Phase III Study (BLOCKSTONE)
2019/05/23: “Notice of Convocation of the 154th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 154th Annual General Meeting of Shareholders”
2019/05/22: SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION THERAPEUTIC AGENT IN ITALY AND POLAND